ArticleP & T : a peer-reviewed journal for formulary management2018
Oritavancin (Orbactiv): A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections.
Article in P & T : a peer-reviewed journal for formulary management, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Oritavancin for the Treatment ofOpen forum infectious diseases · 2025Trial
- Phenotypic and Molecular Characterization of Clinical Isolates of Vancomycin-ResistantPathogens (Basel, Switzerland) · 2026Article
- Is an oritavancin catheter lock solution active against biofilms of staphylococci and enterococci?Heliyon · 2025Article
- Resistance to last-resort antibiotics in enterococci.FEMS microbiology reviews · 2025Review
- In silico molecular targets, docking, dynamics simulation and physiologically based pharmacokinetics modeling of oritavancin.BMC pharmacology & toxicology · 2024Article
- Targeted Liposomal Drug Delivery: Overview of the Current Applications and Challenges.Life (Basel, Switzerland) · 2024Review
- New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Diversity of Antimicrobial Peptides in Silkworm.Life (Basel, Switzerland) · 2023Review
- Structure-activity relationships of antibacterial peptides.Microbial biotechnology · 2023Review
- Therapeutic Options and Outcomes for the Treatment of Children with Gram-Positive Bacteria with Resistances of Concern: A Systematic Review.Antibiotics (Basel, Switzerland) · 2023Review
- Alternatives to Fight Vancomycin-ResistantAntibiotics (Basel, Switzerland) · 2021Review
- Determination of a Tentative Epidemiological Cut-Off Value (ECOFF) for Dalbavancin andAntibiotics (Basel, Switzerland) · 2021Article
- Development and Challenges of Antimicrobial Peptides for Therapeutic Applications.Antibiotics (Basel, Switzerland) · 2020Review
- Accelerated Molecular Dynamics Applied to the Peptaibol Folding Problem.International journal of molecular sciences · 2019Article
- Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms.Microorganisms · 2019Review
- Management of Recurrent Vancomycin-resistantIn vivo (Athens, Greece)Article
- Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome following Dalbavancin and Oritavancin Administration in a Patient with Osteomyelitis.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oritavancin (Orbactiv): a new-generation lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections.
Identifiers
29491695PMC5821239What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.